Abstract
Context: Three recent nested case-control studies conducted in automated databases suggest that users of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have a risk of hip and other osteoporotic fractures half that of non-users of any lipid-lowering drug. However, this comparison may be biased by unmeasured factors associated with treated hyperlipidemias.
Objective: To compare the risk of hip fracture among users of statins and other lipid-lowering agents, which is less susceptible to bias than the comparisons performed in the previous studies.
Design and setting: Retrospective cohort study conducted in the Tennessee Medicaid program between 1 January 1989 through 31 December 1998.
Subjects: New users of all lipid-lowering drugs and randomly selected non-user controls who at baseline were at least 50 years of age and did not have life threatening illness, nursing home residence, or diagnosed dementia or osteoporosis. There were 12 506 persons with new use of statins, 4798 with new use of other lipid lowering drugs, and 17 280 non-user controls.
Main outcome measure: Fracture of the proximal femur (hip), excluding pathological fractures or those resulting from severe trauma.
Results: During 66 690 person years of follow up, there were 186 hip fractures (2.8 per 1000). Relative to non-users, the adjusted incidence rate ratios (95% confidence interval) were 0.62 (0.45 to 0.85) for statin users and 0.44 (0.26 to 0.95) for other lipid-lowering drugs. When compared directly with the other drugs, the adjusted incidence rate ratio for statins was 1.42 (0.83–2.43).
Conclusion: These data provide evidence that the previously observed protective effect of statins may be explained by unmeasured confounding factors.
Full Text
The Full Text of this article is available as a PDF (89.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chan K. A., Andrade S. E., Boles M., Buist D. S., Chase G. A., Donahue J. G., Goodman M. J., Gurwitz J. H., LaCroix A. Z., Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000 Jun 24;355(9222):2185–2188. doi: 10.1016/S0140-6736(00)02400-4. [DOI] [PubMed] [Google Scholar]
- El-Sohemy A. Statin drugs and the risk of fracture. JAMA. 2000 Oct 18;284(15):1921–1922. [PubMed] [Google Scholar]
- Hennekens C. H., Buring J. E., Manson J. E., Stampfer M., Rosner B., Cook N. R., Belanger C., LaMotte F., Gaziano J. M., Ridker P. M. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996 May 2;334(18):1145–1149. doi: 10.1056/NEJM199605023341801. [DOI] [PubMed] [Google Scholar]
- Herrington D. M., Reboussin D. M., Brosnihan K. B., Sharp P. C., Shumaker S. A., Snyder T. E., Furberg C. D., Kowalchuk G. J., Stuckey T. D., Rogers W. J. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000 Aug 24;343(8):522–529. doi: 10.1056/NEJM200008243430801. [DOI] [PubMed] [Google Scholar]
- Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 Aug 19;280(7):605–613. doi: 10.1001/jama.280.7.605. [DOI] [PubMed] [Google Scholar]
- Meier C. R., Schlienger R. G., Kraenzlin M. E., Schlegel B., Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000 Jun 28;283(24):3205–3210. doi: 10.1001/jama.283.24.3205. [DOI] [PubMed] [Google Scholar]
- Mirvis D. M., Chang C. F., Hall C. J., Zaar G. T., Applegate W. B. TennCare--health system reform for Tennessee. JAMA. 1995 Oct 18;274(15):1235–1241. doi: 10.1001/jama.274.15.1235. [DOI] [PubMed] [Google Scholar]
- Omenn G. S., Goodman G. E., Thornquist M. D., Balmes J., Cullen M. R., Glass A., Keogh J. P., Meyskens F. L., Valanis B., Williams J. H. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996 May 2;334(18):1150–1155. doi: 10.1056/NEJM199605023341802. [DOI] [PubMed] [Google Scholar]
- Petitti D. B. Hormone replacement therapy and heart disease prevention: experimentation trumps observation. JAMA. 1998 Aug 19;280(7):650–652. doi: 10.1001/jama.280.7.650. [DOI] [PubMed] [Google Scholar]
- Ray W. A., Griffin M. R., Fought R. L., Adams M. L. Identification of fractures from computerized Medicare files. J Clin Epidemiol. 1992 Jul;45(7):703–714. doi: 10.1016/0895-4356(92)90047-q. [DOI] [PubMed] [Google Scholar]
- Ray W. A., Griffin M. R. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol. 1989 Apr;129(4):837–849. doi: 10.1093/oxfordjournals.aje.a115198. [DOI] [PubMed] [Google Scholar]
- Ray W. A. Psychotropic drugs and injuries among the elderly: a review. J Clin Psychopharmacol. 1992 Dec;12(6):386–396. [PubMed] [Google Scholar]
- Riggs B. L., Melton L. J., 3rd Involutional osteoporosis. N Engl J Med. 1986 Jun 26;314(26):1676–1686. doi: 10.1056/NEJM198606263142605. [DOI] [PubMed] [Google Scholar]
- Tinetti M. E., Doucette J., Claus E., Marottoli R. Risk factors for serious injury during falls by older persons in the community. J Am Geriatr Soc. 1995 Nov;43(11):1214–1221. doi: 10.1111/j.1532-5415.1995.tb07396.x. [DOI] [PubMed] [Google Scholar]
- Tinetti M. E. Prevention of falls and fall injuries in elderly persons: a research agenda. Prev Med. 1994 Sep;23(5):756–762. doi: 10.1006/pmed.1994.1130. [DOI] [PubMed] [Google Scholar]
- Wang P. S., Solomon D. H., Mogun H., Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000 Jun 28;283(24):3211–3216. doi: 10.1001/jama.283.24.3211. [DOI] [PubMed] [Google Scholar]
- van Staa T. P., Wegman S., de Vries F., Leufkens B., Cooper C. Use of statins and risk of fractures. JAMA. 2001 Apr 11;285(14):1850–1855. doi: 10.1001/jama.285.14.1850. [DOI] [PubMed] [Google Scholar]